247 related articles for article (PubMed ID: 25524552)
1. A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo.
Chen TC; Cho HY; Wang W; Nguyen J; Jhaveri N; Rosenstein-Sisson R; Hofman FM; Schönthal AH
Cancer Lett; 2015 Mar; 358(2):144-151. PubMed ID: 25524552
[TBL] [Abstract][Full Text] [Related]
2. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
Pagani E; Falcinelli S; Pepponi R; Turriziani M; Caporaso P; Caporali S; Bonmassar E; D'Atri S
Int J Oncol; 2007 Feb; 30(2):443-51. PubMed ID: 17203227
[TBL] [Abstract][Full Text] [Related]
3. Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas.
Minea RO; Duc TC; Swenson SD; Cho HY; Huang M; Hartman H; Hofman FM; Schönthal AH; Chen TC
PLoS One; 2020; 15(9):e0238238. PubMed ID: 32881880
[TBL] [Abstract][Full Text] [Related]
4. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
Kokkinakis DM; Ahmed MM; Chendil D; Moschel RC; Pegg AE
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3801-7. PubMed ID: 14506174
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapeutic effect of a novel temozolomide analog on nasopharyngeal carcinoma in vitro and in vivo.
Chen TC; Cho HY; Wang W; Wetzel SJ; Singh A; Nguyen J; Hofman FM; Schönthal AH
J Biomed Sci; 2015 Aug; 22(1):71. PubMed ID: 26282951
[TBL] [Abstract][Full Text] [Related]
6. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
7. NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas.
Cho HY; Wang W; Jhaveri N; Lee DJ; Sharma N; Dubeau L; Schönthal AH; Hofman FM; Chen TC
Mol Cancer Ther; 2014 Aug; 13(8):2004-17. PubMed ID: 24994771
[TBL] [Abstract][Full Text] [Related]
8. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
Hermisson M; Klumpp A; Wick W; Wischhusen J; Nagel G; Roos W; Kaina B; Weller M
J Neurochem; 2006 Feb; 96(3):766-76. PubMed ID: 16405512
[TBL] [Abstract][Full Text] [Related]
9. NEO212, a Perillyl Alcohol-Temozolomide Conjugate, Triggers Macrophage Differentiation of Acute Myeloid Leukemia Cells and Blocks Their Tumorigenicity.
Chen TC; Minea RO; Swenson S; Yang Z; Thein TZ; Schönthal AH
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551551
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution.
Boeckmann L; Nickel AC; Kuschal C; Schaefer A; Thoms KM; Schön MP; Thomale J; Emmert S
Melanoma Res; 2011 Jun; 21(3):206-16. PubMed ID: 21460749
[TBL] [Abstract][Full Text] [Related]
11. Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.
Hirose Y; Kreklau EL; Erickson LC; Berger MS; Pieper RO
J Neurosurg; 2003 Mar; 98(3):591-8. PubMed ID: 12650433
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.
Zheng M; Bocangel D; Ramesh R; Ekmekcioglu S; Poindexter N; Grimm EA; Chada S
Mol Cancer Ther; 2008 Dec; 7(12):3842-51. PubMed ID: 19056673
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
Roos WP; Batista LF; Naumann SC; Wick W; Weller M; Menck CF; Kaina B
Oncogene; 2007 Jan; 26(2):186-97. PubMed ID: 16819506
[TBL] [Abstract][Full Text] [Related]
14. Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen.
Pan Q; Yang XJ; Wang HM; Dong XT; Wang W; Li Y; Li JM
Cell Biochem Biophys; 2012 Jan; 62(1):185-91. PubMed ID: 21892781
[TBL] [Abstract][Full Text] [Related]
15. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
Aghi M; Rabkin S; Martuza RL
J Natl Cancer Inst; 2006 Jan; 98(1):38-50. PubMed ID: 16391370
[TBL] [Abstract][Full Text] [Related]
16. A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system.
Alvino E; Castiglia D; Caporali S; Pepponi R; Caporaso P; Lacal PM; Marra G; Fischer F; Zambruno G; Bonmassar E; Jiricny J; D'Atri S
Int J Oncol; 2006 Oct; 29(4):785-97. PubMed ID: 16964376
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial targeting of human O6-methylguanine DNA methyltransferase protects against cell killing by chemotherapeutic alkylating agents.
Cai S; Xu Y; Cooper RJ; Ferkowicz MJ; Hartwell JR; Pollok KE; Kelley MR
Cancer Res; 2005 Apr; 65(8):3319-27. PubMed ID: 15833865
[TBL] [Abstract][Full Text] [Related]
18. The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.
Remington M; Chtchetinin J; Ancheta K; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2009 Feb; 11(1):22-32. PubMed ID: 18812520
[TBL] [Abstract][Full Text] [Related]
19. Genomic and molecular profiling predicts response to temozolomide in melanoma.
Augustine CK; Yoo JS; Potti A; Yoshimoto Y; Zipfel PA; Friedman HS; Nevins JR; Ali-Osman F; Tyler DS
Clin Cancer Res; 2009 Jan; 15(2):502-10. PubMed ID: 19147755
[TBL] [Abstract][Full Text] [Related]
20. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
Kitange GJ; Carlson BL; Schroeder MA; Grogan PT; Lamont JD; Decker PA; Wu W; James CD; Sarkaria JN
Neuro Oncol; 2009 Jun; 11(3):281-91. PubMed ID: 18952979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
